Authorized Generics Do Not Deter Patent Challenges, FTC Says, But May Be Used To Delay Competition
Executive Summary
Authorized generics modestly reduce drug prices during the first 180 days of generic competition and substantially undercut the revenues of competing generic firms, according to the Federal Trade Commission.